SABCS 2021: SUMMIT Reveals Promise of Neratinib in HER2 Mutant Metastatic Breast Cancer
Benefits were observed in heavily pretreated patients with HR-positive/HER2-negative and triple-negative disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.